Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Acquired by Arizona State Retirement System

Arizona State Retirement System lifted its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 16.3% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,077 shares of the company’s stock after buying an additional 1,130 shares during the period. Arizona State Retirement System’s holdings in Keros Therapeutics were worth $369,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. Ameritas Investment Partners Inc. raised its stake in Keros Therapeutics by 14.5% in the 1st quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock worth $169,000 after acquiring an additional 324 shares during the last quarter. Bayesian Capital Management LP purchased a new position in shares of Keros Therapeutics in the first quarter worth about $267,000. CANADA LIFE ASSURANCE Co lifted its holdings in shares of Keros Therapeutics by 117.8% during the first quarter. CANADA LIFE ASSURANCE Co now owns 5,217 shares of the company’s stock worth $345,000 after purchasing an additional 2,822 shares during the period. Perpetual Ltd acquired a new stake in shares of Keros Therapeutics during the first quarter worth about $443,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in Keros Therapeutics by 99.9% in the first quarter. China Universal Asset Management Co. Ltd. now owns 6,916 shares of the company’s stock valued at $458,000 after buying an additional 3,456 shares during the last quarter. 71.56% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Keros Therapeutics

In other Keros Therapeutics news, Director Carl L. Gordon sold 250,000 shares of the company’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the completion of the transaction, the director now directly owns 119,522 shares in the company, valued at $5,260,163.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 22.90% of the stock is owned by corporate insiders.

Keros Therapeutics Stock Down 1.0 %

KROS stock opened at $55.04 on Wednesday. Keros Therapeutics, Inc. has a 52-week low of $27.02 and a 52-week high of $73.00. The firm has a market cap of $1.99 billion, a P/E ratio of -10.69 and a beta of 1.22. The company’s 50-day simple moving average is $48.88 and its 200-day simple moving average is $53.20.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.02). The business had revenue of $0.04 million for the quarter. Keros Therapeutics had a negative return on equity of 44.73% and a negative net margin of 62,012.55%. During the same quarter in the prior year, the company earned ($1.27) EPS. On average, analysts anticipate that Keros Therapeutics, Inc. will post -4.78 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have commented on KROS. Truist Financial restated a “buy” rating and set a $100.00 price objective on shares of Keros Therapeutics in a research note on Tuesday, June 18th. Oppenheimer assumed coverage on shares of Keros Therapeutics in a research report on Tuesday, June 25th. They set an “outperform” rating and a $102.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price target on shares of Keros Therapeutics in a research report on Tuesday, June 18th. Finally, Bank of America decreased their price objective on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a report on Thursday, September 12th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Keros Therapeutics has an average rating of “Buy” and a consensus price target of $89.86.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.